<article title='Carbamazepine'><paragraph><template><target>Infobox drug</target><arg name="verifiedrevid">451682337
</arg><arg name="IUPAC_name">5''H''-dibenzo[''b'',''f'']azepine-5-carboxamide
</arg><arg name="image">Carbamazepine.svg
</arg><arg name="image2">Carbamazepine 3D.png

<space/></arg><arg name="tradename"><space/>Tegretol
</arg><arg name="Drugs.com"><space/>{{drugs.com|monograph|carbamazepine}}
</arg><arg name="DailyMedID"><space/>8d409411-aa9f-4f3a-a52c-fbcb0c3ec053
</arg><arg name="MedlinePlus"><space/>a682237
</arg><arg name="pregnancy_AU"><space/>D
</arg><arg name="pregnancy_US"><space/>D
</arg><arg name="legal_AU"><space/>S4
</arg><arg name="legal_CA"><space/>Rx-only
</arg><arg name="legal_UK"><space/>POM
</arg><arg name="legal_US"><space/>Rx-only
</arg><arg name="legal_status"><space/>
</arg><arg name="routes_of_administration"><space/>Oral

<space/></arg><arg name="bioavailability">~100%<ref name<space/></arg><arg name="protein_bound">70-80%<ref name<space/></arg><arg name="metabolism">[[Liver|Hepatic]]—by [[CYP3A4]], to active [[epoxide]] form (carbamazepine-10,11 epoxide)<ref name<space/></arg><arg name="elimination_half-life">36 hours (single dose), 16-24 hours (repeated dosing)<ref name<space/></arg><arg name="excretion">Urine (72%), feces (28%)<ref name<space/></arg><arg name="IUPHAR_ligand"><space/>5339
</arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|??}}
</arg><arg name="CAS_number">298-46-4
</arg><arg name="CAS_supplemental">{{CAS|85756-57-6}}
</arg><arg name="ATC_prefix">N03
</arg><arg name="ATC_suffix">AF01
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI">3387
</arg><arg name="PubChem">2554
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank">DB00564
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID">2457
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII">33CM23913M
</arg><arg name="KEGG_Ref"><space/>{{keggcite|correct|kegg}}
</arg><arg name="KEGG">D00252
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL">108

<space/></arg><arg name="C">15<space/></arg><arg name="H">12<space/></arg><arg name="N">2<space/></arg><arg name="O">1
</arg><arg name="molecular_weight">236.269&nbsp;g/mol
</arg><arg name="smiles">c1ccc2c(c1)C</arg><arg name="InChI">1/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI">1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey">FFGPTBGBLSHEPO-UHFFFAOYSA-N</arg></template></paragraph><preblock><preline><bold>Carbamazepine</bold><space/>(<bold>CBZ</bold>), sold under the tradename<space/><bold>Tegretol</bold><space/>among others, is a<space/><link><target>medication</target></link><space/>used primarily in the treatment of<space/><link><target>epilepsy</target></link><space/>and<space/><link><target>neuropathic pain</target></link>.<extension extension_name='ref' name="AHFS2015"><template><target>cite web</target><arg name="title">Carbamazepine<space/></arg><arg name="url">http://www.drugs.com/monograph/carbamazepine.html<space/></arg><arg name="work">The American Society of Health-System Pharmacists<space/></arg><arg name="accessdate">Mar 2015</arg></template></extension><space/>For seizures it works as well as<space/><link><target>phenytoin</target></link><space/>and<space/><link><target>valproate</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Nolan</arg><arg name="first">SJ</arg><arg name="author2">Marson, AG<space/></arg><arg name="author3">Pulman, J<space/></arg><arg name="author4"><space/>Tudur Smith, C<space/></arg><arg name="title">Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures.</arg><arg name="journal">The Cochrane database of systematic reviews</arg><arg name="date">23 August 2013</arg><arg name="volume">8</arg><arg name="pages">CD001769</arg><arg name="pmid">23970302</arg><arg name="doi">10.1002/14651858.CD001769.pub2</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Tudur Smith</arg><arg name="first">C</arg><arg name="author2">Marson, AG<space/></arg><arg name="author3">Clough, HE<space/></arg><arg name="author4"><space/>Williamson, PR<space/></arg><arg name="title">Carbamazepine versus phenytoin monotherapy for epilepsy.</arg><arg name="journal">The Cochrane database of systematic reviews</arg><arg name="year">2002</arg><arg name="issue">2</arg><arg name="pages">CD001911</arg><arg name="pmid">12076427</arg><arg name="doi">10.1002/14651858.CD001911</arg></template></extension><space/>It is not effective for<space/><link><target>absence seizure</target><trail>s</trail></link><space/>or<space/><link><target>myoclonic seizure</target><trail>s</trail></link>. It may be used in<space/><link><target>schizophrenia</target></link><space/>along with other medications and as a second line agent in<space/><link><target>bipolar disorder</target></link>.<extension extension_name='ref' name="AHFS2015"></extension><space/>It is taken two to four times per day.<extension extension_name='ref' name="AHFS2015"></extension><space/>A<space/><link><target>controlled release</target></link><space/>formulation is available for which there is tentative evidence showing less side effects.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Powell</arg><arg name="first1">G</arg><arg name="last2">Saunders</arg><arg name="first2">M</arg><arg name="last3">Marson</arg><arg name="first3">AG</arg><arg name="title">Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.</arg><arg name="journal">The Cochrane database of systematic reviews</arg><arg name="date">3 February 2014</arg><arg name="volume">2</arg><arg name="pages">CD007124</arg><arg name="pmid">24488654</arg><arg name="doi">10.1002/14651858.CD007124.pub3</arg></template></extension></preline></preblock><preblock><preline>Common side effects include<space/><link><target>nausea</target></link><space/>and<space/><link><target>drowsiness</target></link>. Serious side effects may include skin rashes, decreased<space/><link><target>bone marrow</target></link><space/>function,<space/><link><target>suicidal thoughts</target></link>, or confusion. It should not be used in those with a history of bone marrow problems. Use during<space/><link><target>pregnancy</target></link><space/>may cause harm to the baby; however stopping it in pregnant women with seizures is not recommended. Its use during<space/><link><target>breastfeeding</target></link><space/>is not recommended. Care should be taken in those with either kidney or liver problems.<extension extension_name='ref' name="AHFS2015"></extension></preline></preblock><preblock><preline>Carbamazepine was discovered in 1953 by Swiss chemist Walter Schindler.<extension extension_name='ref'><template><target>cite book</target><arg name="last1">Smith</arg><arg name="first1">Howard S.</arg><arg name="title">Current therapy in pain</arg><arg name="date">2009</arg><arg name="publisher">Saunders/Elsevier</arg><arg name="location">Philadelphia</arg><arg name="isbn">9781416048367</arg><arg name="page">460</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>It was first marketed in 1962.<extension extension_name='ref'><template><target>cite book</target><arg name="last1">Moshé</arg><arg name="first1">Solomon</arg><arg name="title">The treatment of epilepsy</arg><arg name="date">2009</arg><arg name="publisher">Wiley-Blackwell</arg><arg name="location">Chichester, UK</arg><arg name="isbn">9781444316674</arg><arg name="page">xxix</arg><arg name="edition">3</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>It is available as a<space/><link><target>generic medication</target></link><space/>and is not very expensive.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Principles and practice of stereotactic radiosurgery</arg><arg name="date">2008</arg><arg name="publisher">Springer</arg><arg name="location">New York</arg><arg name="isbn">9780387710709</arg><arg name="page">536</arg><arg name="url">https://books.google.ca/books?id</arg></template></extension><space/>It is on the<space/><link><target>WHO Model List of Essential Medicines</target></link>, the most important medications needed in a basic<space/><link><target>health system</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="title">WHO Model List of Essential Medicines</arg><arg name="format">PDF</arg><arg name="url">http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua</arg><arg name="work">World Health Organization</arg><arg name="accessdate">22 April 2014</arg><arg name="date">October 2013</arg></template></extension></preline></preblock><heading level='2'>Medical uses</heading><paragraph><link><target>File:Tegretol.jpg</target><part>thumb</part><part>Tegretol 200-mg CR (made in<space/><link><target>NZ</target></link>)</part></link>Carbamazepine is typically used for the treatment of<space/><link><target>seizure disorders</target></link><space/>and<space/><link><target>neuropathic pain</target></link>.<extension extension_name='ref' name="AHFS2015"></extension><space/>It is used<space/><link><target>off-label use</target><part>off-label</part></link><space/>as a second-line treatment for bipolar disorder and in combination with an<space/><link><target>antipsychotic</target></link><space/>in some cases of<space/><link><target>schizophrenia</target></link><space/>when treatment with a conventional antipsychotic alone has failed.<extension extension_name='ref' name="AHFS2015"></extension><extension extension_name='ref' name="Ceron-Litvoc"><template><target>cite journal</target><arg name="author">Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS<space/></arg><arg name="title">Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials<space/></arg><arg name="journal">Hum Psychopharmacol<space/></arg><arg name="volume">24<space/></arg><arg name="issue">1<space/></arg><arg name="pages">19–28<space/></arg><arg name="date">January 2009<space/></arg><arg name="pmid">19053079<space/></arg><arg name="doi">10.1002/hup.990</arg></template></extension></paragraph><paragraph>In the United States, the<space/><link><target>Food and Drug Administration</target><part>FDA</part></link>-approved medical uses are<space/><link><target>epilepsy</target></link><space/>(including<space/><link><target>partial seizure</target><trail>s</trail></link>, generalized<space/><link><target>tonic-clonic seizure</target><trail>s</trail></link><space/>and<space/><link><target>mixed seizure</target><trail>s</trail></link>),<space/><link><target>trigeminal neuralgia</target></link>, and<space/><link><target>mania</target><part>manic</part></link><space/>and<space/><link><target>mixed state (psychiatry)</target><part>mixed episodes</part></link><space/>of<space/><link><target>bipolar I disorder</target></link>.<extension extension_name='ref' name="Lexi-Comp"></extension></paragraph><paragraph>It is unclear if there is a significant difference in effectiveness between controlled release and immediate release formulations in epilepsy.<extension extension_name='ref' name="Cochrane2014"></extension><space/>Controlled release forms might, however, have lower risks of side effects.<extension extension_name='ref' name="Cochrane2014"><template><target>cite journal</target><arg name="last1">Powell</arg><arg name="first1">G</arg><arg name="last2">Saunders</arg><arg name="first2">M</arg><arg name="last3">Rigby</arg><arg name="first3">A</arg><arg name="last4">Marson</arg><arg name="first4">AG</arg><arg name="title">Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.</arg><arg name="journal">The Cochrane database of systematic reviews</arg><arg name="date">3 December 2014</arg><arg name="volume">12</arg><arg name="pages">CD007124</arg><arg name="pmid">25470302</arg><arg name="doi">10.1002/14651858.CD007124.pub4</arg></template></extension></paragraph><heading level='2'>Adverse effects</heading><paragraph>In the US, the label for carbamazepine contains warnings concerning:</paragraph><list type='bullet'><listitem>effects on the<space/><link><target>Hematology</target><part>body's production of red blood cells, white blood cells, and platelets</part></link>: rarely, there are major effects of<space/><link><target>aplastic anemia</target></link><space/>and<space/><link><target>agranulocytosis</target></link><space/>reported and more commonly, there are minor changes such as decreased<space/><link><target>Leukocyte</target><part>white blood cell</part></link><space/>or<space/><link><target>platelet</target></link><space/>counts, that do not progress to more serious problems.<extension extension_name='ref' name="TGA"></extension><space/></listitem><listitem>increased risks of suicide<extension extension_name='ref' name="TGA"></extension></listitem><listitem>risk of seizures, if the person stops taking the drug abruptly<extension extension_name='ref' name="TGA"></extension></listitem><listitem>risks to the fetus in women who are pregnant, specifically congenital malformations like<space/><link><target>spina bifida</target></link>, and developmental disorders.<extension extension_name='ref' name="TGA"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Jentink<space/></arg><arg name="first">J<space/></arg><arg name="author2">Dolk, H<space/></arg><arg name="author3">Loane, MA<space/></arg><arg name="author4">Morris, JK<space/></arg><arg name="author5">Wellesley, D<space/></arg><arg name="author6">Garne, E<space/></arg><arg name="author7">de Jong-van den Berg, L<space/></arg><arg name="author8">EUROCAT Antiepileptic Study Working Group<space/></arg><arg name="title">Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study<space/></arg><arg name="journal">BMJ (Clinical research ed.)<space/></arg><arg name="date">2010-12-02<space/></arg><arg name="volume">341<space/></arg><arg name="pages">c6581<space/></arg><arg name="doi">10.1136/bmj.c6581<space/></arg><arg name="pmid">21127116<space/></arg><arg name="pmc">2996546</arg></template></extension></listitem></list><paragraph>Common<space/><link><target>adverse drug reaction</target><part>adverse effects</part></link><space/>may include drowsiness, dizziness, headaches and migraines,<space/><link><target>motor coordination</target></link><space/>impairment, nausea, vomiting, and/or constipation. Alcohol use while taking carbamazepine may lead to enhanced depression of the<space/><link><target>central nervous system</target></link>.<extension extension_name='ref' name="TGA"></extension><space/>Less common side effects may include increased risk of seizures in people with<space/><link><target>Causes of seizures#Diseases</target><part>mixed seizure disorders</part></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1124/jpet.106.10496<space/></arg><arg name="title">The Mechanism of Carbamazepine Aggravation of Absence Seizures<space/></arg><arg name="year">2006<space/></arg><arg name="author">Lige Liu, Thomas Zheng, Margaret J. Morris, Charlott Wallengren, Alison L. Clarke, Christopher A. Reid, Steven Petrou and Terence J. O'Brien<space/></arg><arg name="journal">JPET<space/></arg><arg name="volume">319<space/></arg><arg name="issue">2<space/></arg><arg name="pages">790–798<space/></arg><arg name="pmid">16895979<space/></arg><arg name="url">http://jpet.aspetjournals.org/content/319/2/790.abstract</arg></template></extension><space/><link><target>arrhythmia</target><part>abnormal heart rhythms</part></link>, blurry or<space/><link><target>Diplopia</target><part>double vision</part></link>.<extension extension_name='ref' name="TGA"></extension><space/>Also, rare case reports of an auditory side effect have been made, whereby patients perceive sounds about a<space/><link><target>semitone</target></link><space/>lower than previously; this unusual side effect is usually not noticed by most people, and disappears after the person stops taking carbamazepine.<extension extension_name='ref'><template><target>cite journal</target><arg name="pmid"><space/>16876011<space/></arg><arg name="doi">10.1016/j.pediatrneurol.2006.01.011<space/></arg><arg name="volume">35<space/></arg><arg name="title">Carbamazepine-induced transient auditory pitch-perception deficit.<space/></arg><arg name="date">Aug 2006<space/></arg><arg name="journal">Pediatr Neurol<space/></arg><arg name="pages">131–4</arg></template></extension></paragraph><heading level='3'>Interactions</heading><paragraph>Carbamazepine has a potential for<space/><link><target>drug interaction</target><trail>s</trail></link>; caution should be used in combining other medicines with it, including other antiepileptics and mood stabilizers.<extension extension_name='ref' name="Lexi-Comp"><template><target>cite web</target><arg name="url">http://www.merck.com/mmpe/lexicomp/carbamazepine.html<space/></arg><arg name="title">Carbamazepine<space/></arg><arg name="date">February 2009<space/></arg><arg name="author">Lexi-Comp<space/></arg><arg name="work">[[Merck Manual of Diagnosis and Therapy|The Merck Manual Professional]]<space/></arg><arg name="archiveurl">http://www.webcitation.org/5uKvOP99i<space/></arg><arg name="archivedate">2010-11-18<space/></arg><arg name="deadurl">no</arg></template><space/>Retrieved on May 3, 2009.</extension><space/>Lower levels of carbamazepine are seen when administrated with<space/><link><target>phenobarbital</target></link>,<space/><link><target>phenytoin</target></link><space/>(Dilantin), or<space/><link><target>primidone</target></link><space/>(Mysoline), which can result in breakthrough seizure activity. Carbamazepine, as a<space/><link><target>CYP450</target></link><space/>inducer, may increase clearance of many drugs, decreasing their concentration in the blood to subtherapeutic levels and reducing their desired effects.<extension extension_name='ref' name="urleMedicine- Toxicity, Carbamazepine"><template><target>cite web</target><arg name="url">http://www.emedicine.com/emerg/topic77.htm<space/></arg><arg name="title">eMedicine - Toxicity, Carbamazepine<space/></arg><arg name="work"><space/></arg><arg name="accessdate"><space/></arg><arg name="archiveurl">http://www.webcitation.org/5ZpbVBsOJ<space/></arg><arg name="archivedate">2008-08-04<space/></arg><arg name="deadurl">no</arg></template></extension><space/>Drugs that are more rapidly metabolized with carbamazepine include<space/><link><target>warfarin</target></link>,<space/><link><target>lamotrigine</target></link>,<space/><link><target>phenytoin</target></link>,<space/><link><target>theophylline</target></link>, and<space/><link><target>valproic acid</target></link>.<extension extension_name='ref' name="Lexi-Comp"></extension><space/>Drugs that decrease the metabolism of carbamazepine or otherwise increase its levels include<space/><link><target>erythromycin</target></link>,<extension extension_name='ref' name="Stafstrom"><template><target>cite journal</target><arg name="author">Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR<space/></arg><arg name="title">Erythromycin-induced carbamazepine toxicity: a continuing problem<space/></arg><arg name="journal">Arch Pediatr Adolesc Med<space/></arg><arg name="volume">149<space/></arg><arg name="issue">1<space/></arg><arg name="pages">99–101<space/></arg><arg name="date">January 1995<space/></arg><arg name="pmid">7827672<space/></arg><arg name="doi"><space/>10.1001/archpedi.1995.02170130101025<space/></arg><arg name="url">http://archpedi.ama-assn.org/cgi/pmidlookup?view</arg><arg name="archiveurl">http://www.webcitation.org/5uKvQB98w<space/></arg><arg name="archivedate">2010-11-18<space/></arg><arg name="deadurl">no</arg></template></extension><space/><link><target>cimetidine</target></link>,<space/><link><target>propoxyphene</target></link>, and<space/><link><target>calcium channel blocker</target><trail>s</trail></link>.<extension extension_name='ref' name="Lexi-Comp"></extension><space/>Carbamazepine also increases the metabolism of the hormones in<space/><link><target>birth control pill</target><trail>s</trail></link><space/>and can reduce their effectiveness, potentially leading to unexpected pregnancies.<extension extension_name='ref' name="Lexi-Comp"></extension><space/>As a drug that induces cytochrome P450 enzymes, it accelerates elimination of many benzodiazepines and decreases their action.<extension extension_name='ref' name="isbn1-58829-211-8"><template><target>cite book</target><arg name="author">Moody D<space/></arg><arg name="editor">Raymon LP, Mozayani A (eds.)<space/></arg><arg name="title">Handbook of Drug Interactions: a Clinical and Forensic Guide<space/></arg><arg name="publisher">Humana<space/></arg><arg name="year">2004<space/></arg><arg name="pages">3–88<space/></arg><arg name="chapter">Drug interactions with benzodiazepines<space/></arg><arg name="isbn">1-58829-211-8</arg></template></extension></paragraph><paragraph>Valproic acid and<space/><link><target>valnoctamide</target></link><space/>both inhibit<space/><link><target>epoxide hydrolase</target><part>microsomal epoxide hydrolase</part></link><space/>(MEH), the enzyme responsible for the breakdown of carbamazepine-10,11 epoxide into inactive metabolites.<extension extension_name='ref'><template><target>cite book</target><arg name="last">Gonzalez<space/></arg><arg name="first">Frank J.<space/></arg><arg name="author2">Robert H. Tukey<space/></arg><arg name="editor">Laurence Brunton, John Lazo, Keith Parker (eds.)<space/></arg><arg name="title">[[Goodman & Gilman's The Pharmacological Basis of Therapeutics]]<space/></arg><arg name="edition">11th<space/></arg><arg name="year">2006<space/></arg><arg name="publisher">[[McGraw-Hill]]<space/></arg><arg name="location">New York<space/></arg><arg name="isbn">978-0-07-142280-2<space/></arg><arg name="page">79<space/></arg><arg name="chapter">Drug Metabolism</arg></template></extension><space/>By inhibiting MEH, valproic acid and valnoctamide cause a build-up of the active metabolite, prolonging the effects of carbamazepine and delaying its excretion.</paragraph><paragraph>Grapefruit juice raises the<space/><link><target>bioavailability</target></link><space/>of carbamazepine by inhibiting CYP3A4 enzymes in the gut wall and in the liver.<extension extension_name='ref' name="TGA"></extension></paragraph><heading level='3'>Pharmacogenetics</heading><paragraph>Dangerous and potentially fatal skin reactions, including<space/><link><target>StevensJohnson syndrome</target></link><space/>and<space/><link><target>toxic epidermal necrolysis</target></link>, caused by carbamazepine therapy are significantly more common in patients with a particular<space/><link><target>human leukocyte antigen</target></link><space/>allele,<space/><link><target>HLA-B75</target><part>HLA-B*1502</part></link>.<extension extension_name='ref' name="carbamazepinelabel"><template><target>cite web</target><arg name="title">Carbamazepine Drug Label</arg><arg name="website">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid</arg></template></extension><space/><link><target>Odds ratios</target></link><space/>for the development of Stevens-Johnson syndrome or<space/><link><target>toxic epidermal necrolysis</target></link><space/>in patients who carry the allele can be in the double, triple or even quadruple digits, depending on the population studied.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Kaniwa</arg><arg name="first1">N</arg><arg name="last2">Saito</arg><arg name="first2">Y</arg><arg name="title">Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.</arg><arg name="journal">Journal of human genetics</arg><arg name="date">June 2013</arg><arg name="volume">58</arg><arg name="issue">6</arg><arg name="pages">317–26</arg><arg name="pmid">23635947</arg><arg name="doi">10.1038/jhg.2013.37</arg></template></extension><extension extension_name='ref' name="pmid24597466"><template><target>cite journal</target><arg name="last1">Amstutz</arg><arg name="first1">U</arg><arg name="last2">Shear</arg><arg name="first2">NH</arg><arg name="last3">Rieder</arg><arg name="first3">MJ</arg><arg name="last4">Hwang</arg><arg name="first4">S</arg><arg name="last5">Fung</arg><arg name="first5">V</arg><arg name="last6">Nakamura</arg><arg name="first6">H</arg><arg name="last7">Connolly</arg><arg name="first7">MB</arg><arg name="last8">Ito</arg><arg name="first8">S</arg><arg name="last9">Carleton</arg><arg name="first9">BC</arg><arg name="last10">CPNDS clinical recommendation</arg><arg name="first10">group</arg><arg name="title">Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.</arg><arg name="journal">Epilepsia</arg><arg name="date">April 2014</arg><arg name="volume">55</arg><arg name="issue">4</arg><arg name="pages">496–506</arg><arg name="pmid">24597466</arg><arg name="doi">10.1111/epi.12564</arg></template></extension><space/><link><target>HLA-B75</target><part>HLA-B*1502</part></link><space/>occurs almost exclusively in patients with ancestry across broad areas of Asia, but has a very low or absent frequency in European, Japanese, Korean and African populations.<extension extension_name='ref' name="carbamazepinelabel"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Leckband</arg><arg name="first1">SG</arg><arg name="last2">Kelsoe</arg><arg name="first2">JR</arg><arg name="last3">Dunnenberger</arg><arg name="first3">HM</arg><arg name="last4">George AL</arg><arg name="first4">Jr</arg><arg name="last5">Tran</arg><arg name="first5">E</arg><arg name="last6">Berger</arg><arg name="first6">R</arg><arg name="last7">Müller</arg><arg name="first7">DJ</arg><arg name="last8">Whirl-Carrillo</arg><arg name="first8">M</arg><arg name="last9">Caudle</arg><arg name="first9">KE</arg><arg name="last10">Pirmohamed</arg><arg name="first10">M</arg><arg name="last11">Clinical Pharmacogenetics Implementation</arg><arg name="first11">Consortium</arg><arg name="title">Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.</arg><arg name="journal">Clinical pharmacology and therapeutics</arg><arg name="date">September 2013</arg><arg name="volume">94</arg><arg name="issue">3</arg><arg name="pages">324–8</arg><arg name="pmid">23695185</arg><arg name="doi">10.1038/clpt.2013.103</arg></template></extension><space/>However, the HLA-A*31:01 allele has been shown to be a strong predictor of both mild and severe adverse reactions to carbamazepine among Japanese and Europeans.<extension extension_name='ref' name="pmid24597466"></extension></paragraph><heading level='2'>Pharmacokinetics</heading><paragraph>Carbamazepine is relatively slowly but well absorbed after oral administration. Its plasma half-life is about 30 hours when it is given as single dose, but it is a strong inducer of hepatic enzymes and the plasma half-life shortens to about 15 hours when it is given repeatedly.<space/><template><target>mcn</target><arg name="date">December 2014</arg></template></paragraph><heading level='2'>Mechanism of action</heading><paragraph>The mechanism of action of carbamazepine and its derivatives is relatively well understood. Carbamazepine stabilizes the inactivated state of<space/><link><target>voltage-gated sodium channel</target><trail>s</trail></link>, making fewer of these channels available to subsequently open. This leaves the affected cells less excitable until the drug dissociates.<template><target>Citation needed</target><arg name="date">February 2014</arg></template><space/>Carbamazepine is also a<space/><link><target>GABA receptor agonist</target></link>, as it has also been shown to potentiate<space/><link><target>GABA receptor</target><trail>s</trail></link><space/>made up of alpha1, beta2, and gamma2 subunits.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Granger P.<space/></arg><arg name="year"><space/>1995<space/></arg><arg name="title"><space/>Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Mol. Pharmacol<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>1189–1196<space/></arg><arg name="display-authors">etal</arg></template></extension><space/>This mechanism may contribute to its efficacy in neuropathic pain and manic-depressive illness. Laboratory research has further demonstrated that carbamazepine is a<space/><link><target>serotonin releasing agent</target></link><space/>and possibly even a<space/><link><target>serotonin reuptake inhibitor</target></link>.<space/><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Dailey</arg><arg name="first1">JW</arg><arg name="last2">Reith</arg><arg name="first2">ME</arg><arg name="last3">Steidley</arg><arg name="first3">KR</arg><arg name="last4">Milbrandt</arg><arg name="first4">JC</arg><arg name="last5">Jobe</arg><arg name="first5">PC</arg><arg name="title">Carbamazepine-induced release of serotonin from rat hippocampus in vitro.</arg><arg name="journal">Epilepsia</arg><arg name="date">1998</arg><arg name="pmid">9776325</arg><arg name="url">http://www.ncbi.nlm.nih.gov/pubmed/9776325</arg></template></extension><space/><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Dailey</arg><arg name="first1">JW</arg><arg name="last2">Reith</arg><arg name="first2">ME</arg><arg name="last3">Yan</arg><arg name="first3">QS</arg><arg name="last4">Li</arg><arg name="first4">MY</arg><arg name="last5">Jobe</arg><arg name="first5">PC</arg><arg name="title">Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+.</arg><arg name="journal">European Journal of Pharmacology</arg><arg name="date">11 June 1997</arg><arg name="pmid">9218697</arg><arg name="url">http://www.ncbi.nlm.nih.gov/pubmed/9218697</arg></template></extension><space/><extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Kawata</arg><arg name="first1">Yuko</arg><arg name="last2">Okada</arg><arg name="first2">Motohiro</arg><arg name="last3">Murakami</arg><arg name="first3">Takuya</arg><arg name="last4">Kamata</arg><arg name="first4">Akihisa</arg><arg name="last5">Zhu</arg><arg name="first5">Gang</arg><arg name="last6">Kaneko</arg><arg name="first6">Sunao</arg><arg name="title">Pharmacological discrimination between effects of carbamazepine on hippocampal basal evoked serotonin release</arg><arg name="journal">British Journal of Pharmacology</arg><arg name="date">2001</arg><arg name="volume">133</arg><arg name="issue">4</arg><arg name="pages">557–567</arg><arg name="doi">10.1038/sj.bjp.0704104</arg><arg name="pmid">1572811</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph>Carbamazepine was discovered by chemist Walter Schindler at J.R. Geigy AG (now part of<space/><link><target>Novartis</target></link>) in<space/><link><target>Basel</target></link>,<space/><link><target>Switzerland</target></link>, in 1953.<extension extension_name='ref' name="Scott1993">D.F. Scott. &quot;Carbamazepine&quot;. Chapter 8 in The History of Epileptic Therapy: An Account of How Medication was Developed. History of Medicine Series. CRC Press, 1993 ISBN 9781850703914</extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Schindler W, Häfliger F<space/></arg><arg name="title">Über Derivate des Iminodibenzyls<space/></arg><arg name="journal">[[Helvetica Chimica Acta]]<space/></arg><arg name="year">1954<space/></arg><arg name="volume">37<space/></arg><arg name="issue">2<space/></arg><arg name="pages">472–83.<space/></arg><arg name="doi">10.1002/hlca.19540370211</arg></template></extension><space/>It was first marketed as a drug to treat epilepsy in Switzerland in 1963 under the brand name &quot;Tegretol&quot;; its use for<space/><link><target>trigeminal neuralgia</target></link><space/>(formerly known as tic douloureux) was introduced at the same time.<extension extension_name='ref' name="Scott1993"></extension><space/>It has been used as an anticonvulsant and antiepileptic in the<space/><link><target>United Kingdom</target><part>UK</part></link><space/>since 1965, and has been approved in the<space/><link><target>United States</target><part>US</part></link><space/>since 1974.</paragraph><paragraph>In 1971, Drs. Takezaki and Hanaoka first used carbamazepine to control mania in patients refractory to antipsychotics (<link><target>Lithium pharmacology</target><part>lithium</part></link><space/>was not available in Japan at that time). Dr. Okuma, working independently, did the same thing with success. As they were also epileptologists, they had some familiarity with the antiaggression effects of this drug. Carbamazepine was studied for bipolar disorder throughout the 1970s.<extension extension_name='ref' name="pmid9682927"><template><target>cite journal</target><arg name="author">Okuma T, Kishimoto A<space/></arg><arg name="title">A history of investigation on the mood stabilizing effect of carbamazepine in Japan<space/></arg><arg name="journal">Psychiatry Clin. Neurosci.<space/></arg><arg name="volume">52<space/></arg><arg name="issue">1<space/></arg><arg name="pages">3–12<space/></arg><arg name="date">February 1998<space/></arg><arg name="pmid">9682927<space/></arg><arg name="doi">10.1111/j.1440-1819.1998.tb00966.x</arg></template></extension></paragraph><heading level='2'>Environmental fate</heading><paragraph><template><target>Main</target><arg>Environmental impact of pharmaceuticals and personal care products</arg></template></paragraph><paragraph>Carbamazepine has been detected in wastewater<space/><link><target>effluent</target></link>.<extension extension_name='ref' name="Prosser">Prosser RS, Sibley PK2. Human health risk assessment of pharmaceuticals and personal care products in plant tissue due to biosolids and manure amendments, and wastewater irrigation. Environ Int. 2014 Dec 5;75C:223-233. doi: 10.1016/j.envint.2014.11.020. PMID 25486094</extension><template><target>rp</target><arg>224</arg></template><space/>Field and laboratory studies have been conducted to understand the accumulation of carbamazepine in food plants grown in soil treated with<space/><link><target>sludge</target></link>, which vary with respect to the concentrations of carbamazepine present in sludge and in the concentrations of sludge in the soil; taking into account only studies that used concentrations normally found, a 2014 review found that &quot;the accumulation of carbamazepine into plants grown in soil amended with biosolids poses a<space/><italics>de minimis</italics><space/>risk to human health according to the approach.&quot;<extension extension_name='ref' name="Prosser"></extension><template><target>rp</target><arg>227</arg></template></paragraph><heading level='2'>Brand names</heading><paragraph>Carbamazepine is available worldwide under many brand names.<extension extension_name='ref'>drugs.com<space/><link type='external' href='http://www.drugs.com/international/carbamazepine.html'>drugs.com international listings for carbamazepine</link><space/>Page accessed June 3, 2015</extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Imipramine</target></link></listitem></list><list type='bullet'><listitem><link><target>Oxcarbazepine</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg>2</arg></template></paragraph><heading level='2'>External links</heading><paragraph><template><target>Commons category</target></template></paragraph><list type='bullet'><listitem><link type='external' href='http://wayback.archive.org/web/20140629011455/http://psycheducation.org/depression/meds/carbamazepine.htm'>Carbamazepine overview</link><space/>from PsychEducation.org</listitem><listitem><link type='external' href='http://www.medscape.com/viewarticle/410736_4'>Extensive review of the effects of carbamazepine in pregnancy and breastfeeding</link></listitem></list><paragraph><template><target>Anticonvulsants</target></template><template><target>Mood stabilizers</target></template><template><target>Neuropathic pain and fibromyalgia pharmacotherapies</target></template><template><target>Channelergics</target></template><template><target>GABAAR PAMs</target></template><template><target>Nuclear receptor ligands</target></template><template><target>Tricyclics</target></template></paragraph><paragraph><link><target>Category:Anticonvulsants</target></link><link><target>Category:Mood stabilizers</target></link><link><target>Category:Prodrugs</target></link><link><target>Category:Ureas</target></link><link><target>Category:World Health Organization essential medicines</target></link><link><target>Category:Dibenzazepines</target></link><link><target>Category:GABAA receptor positive allosteric modulators</target></link><link><target>Category:RTT</target></link></paragraph></article>